The demand for influenza vaccine has increased significantly. The companys production capacity has doubled and there is ample room for growth

category:Finance
 The demand for influenza vaccine has increased significantly. The companys production capacity has doubled and there is ample room for growth


September to October is the best time to get influenza vaccine. Recently, novel coronavirus pneumonia has been affected by the new crown pneumonia in Beijing, Gansu, Sichuan and Jilin. The demand for influenza vaccination in autumn and winter has increased over the same period in previous years. According to the statistics of Southwest Securities, as of August (this years influenza vaccine has been approved and issued since July), a total of 10.54 million influenza vaccines have been approved and issued this year, an increase of 52% over the same period of last year. 6.29 million trivalent influenza vaccines were approved and issued, with a year-on-year increase of 12%, accounting for 60%. 4.25 million tetravalent influenza vaccines were approved and issued, with a year-on-year increase of 224%, accounting for 40%. Among the four price approved influenza vaccines, 2.89 million influenza vaccines were issued, accounting for 68% of the total.

The novel coronavirus pneumonia, Zheng Wei, pointed out that autumn and winter are the prevalent seasons of common respiratory diseases such as influenza, Haemophilus influenzae infection, Streptococcus pneumoniae infection, etc. the epidemic situation of new crown pneumonia in China in autumn and winter is superimposed with the epidemic of respiratory diseases such as influenza, and the complexity and prevention and control of prevention and control are more difficult. In addition, in view of the improvement of peoples awareness of disease prevention and control under the new epidemic situation, the publics attention and demand for influenza and pneumonia vaccines may increase significantly this year.

The space for tetravalent influenza vaccine is expected to reach 10 billion yuan, and the biological capacity of Hualan will double

The release of terminal demand for tetravalent influenza vaccine depends on the improvement of peoples awareness of the hazards of influenza and influenza vaccine, and the outbreak of the epidemic has raised peoples awareness of prevention. More regions will incorporate vaccines into immunization programs or medical insurance coverage, and the penetration rate is expected to increase. Regardless of the production capacity, Sheng Lihua of Minsheng securities estimates that the space for tetravalent influenza vaccine will reach 10 billion yuan, and the current market regulation The model is more than 2 billion yuan, with 5 times of growth space. According to the data, in 2018, about 8.5 million influenza vaccines were approved and issued, accounting for more than 50% of the total number of influenza vaccines issued in China; in 2019, there were 1300 influenza vaccines, accounting for 38% of the total batch issuance of last years influenza vaccines, making it the most important influenza vaccine manufacturer in China. Sheng Lihua of Minsheng Securities believes that the company strives to expand the scale of the vaccine industry, and is expected to maintain a dominant position in the influenza vaccine market, accounting for about 35% - 40% of the influenza market. The companys influenza vaccine revenue scale is expected to reach about 4 billion yuan, with an estimated net profit margin of 30% - 35%, corresponding net profit of 1.2-1.4 billion yuan, with sufficient growth space. Source: Science and technology innovation board daily editor: Zhong Qiming_ NF5619

The release of terminal demand for tetravalent influenza vaccine depends on the improvement of peoples awareness of the hazards of influenza and influenza vaccine, and the outbreak of the epidemic has raised peoples awareness of prevention. More regions will incorporate vaccines into immunization programs or medical insurance coverage, and the penetration rate is expected to increase. Regardless of the production capacity, Sheng Lihua of Minsheng securities estimates that the space for tetravalent influenza vaccine will reach 10 billion yuan, and the current market regulation The model is more than 2 billion yuan, with 5 times of growth space.

According to the data, in 2018, about 8.5 million influenza vaccines were approved and issued, accounting for more than 50% of the total number of influenza vaccines issued in China; in 2019, there were 1300 influenza vaccines, accounting for 38% of the total batch issuance of last years influenza vaccines, making it the most important influenza vaccine manufacturer in China.

Sheng Lihua of Minsheng Securities believes that the company strives to expand the scale of the vaccine industry, and is expected to maintain a dominant position in the influenza vaccine market, accounting for about 35% - 40% of the influenza market. The companys influenza vaccine revenue scale is expected to reach about 4 billion yuan, with an estimated net profit margin of 30% - 35%, corresponding net profit of 1.2-1.4 billion yuan, with sufficient growth space.